This year's ViVE conference featured a variety of news announcements — from company launches to new products to partnerships to acquisitions and more. In this list, MedCity News compiled short summaries for nine of the conference's most notable announcements.
Amazon launched a new initiative to help connect people to digital health benefits that they may not know are available to them. Omada Health is its first partner. CEO Sean Duffy said his company stood out from the many other virtual diabetes care companies out there because about 20 million Americans — many of whom shop on Amazon — are eligible for Omada's programs.
It makes sense that when care navigation prioritizes the patient and better links them to care by reducing barriers and smoothing out the road to seeing a provider, the patient experiences better outcomes. Better outcomes also translates to fewer hospital readmissions, saving money for both patients and their employers.
Omada's new program provides coaching, peer support and educational materials to patients struggling with chronic obesity and taking GLP-1s. The company chose not to prescribe the weight loss drugs itself.
Steve Driver is an interventional cardiologist as well as medical director of digital therapeutics at Advocate Aurora Health, which last year merged with Atrium Health. In this episode, he talked about a pilot involving Omada Health targeting a prediabetes population, among other things.
Insurers and employers are optimistic about the possibilities of virtual care, but they're not very enthusiastic about the care modality's larger influence on the healthcare industry, according to a recent report. Just 29% of employers and 34% of payers and benefits consultants said that virtual care will drastically change the way healthcare is provided and outcomes are achieved.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Omada got funds from two new investors - Fidelity Management & Research Company and aMoon as well as existing ones. Verily's Onduo is bringing its virtual diabetes management platform to an integrated care delivery and health plan that has 6 million members in Pennsylvania, West Virginia, Delaware, and New York.
Omada’s chief privacy and regulatory officer shared how she set the stage for new interoperability rules while working at the ONC, and how digital health companies should navigate them.
CNBC's healthcare reporter has left the world of journalism behind to become a venture capitalist at OMERS Ventures. In an interview, she makes some healthcare predictions about 2021 and beyond.
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. A validated program that can effectively help people manage their disease is invaluable, especially at a time when in-person physician visits are unavailable.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Omada Health acquired Physera Health, a company that offers telehealth physical therapy appointments. The deal would add another digital health platform to Omada's toolbox, which includes solutions for diabetes, hypertension and behavioral health.
With worries over health and the economy affecting most employees, companies are looking for ways to roll out more mental health tools. In turn, many digital health startups have found new clients.
The markets may be battered, the economy shaken by Covid-19 concerns, but that didn't prevent a discussion with a top digital health CEO about the attractiveness of an IPO.
The company, which will be listed on the Nasdaq exchange under the ticker symbol "LVGO," offers tech-enabled solutions that help to monitor and manage people with chronic conditions like diabetes, hypertension and behavioral health issues.
The round also included participation from previous investors including Cigna Ventures, Andreessen Horowitz, Kaiser Permanente, Sanofi Ventures and Norwest Venture Partners, reportedly values the company at $600 million.
